Barclays
NWBO

Barclays’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Barclays’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5,467
Closed -$3K – 7119
2016
Q2 		$3K Buy
+5,467
New +$5.84K ﹤0.01% 5915
2015
Q4 		– Sell
-244
Closed -$1K – 7325
2015
Q3 		$1K Sell
244
-651
-73% -$6.09K ﹤0.01% 6791
2015
Q2 		$8K Sell
895
-337
-27% -$2.95K ﹤0.01% 6248
2015
Q1 		$9K Sell
1,232
-954
-44% -$6.42K ﹤0.01% 6327
2014
Q4 		$11K Buy
2,186
+1,817
+492% +$9.3K ﹤0.01% 6700
2014
Q3 		$2K Sell
369
-411
-53% -$2.53K ﹤0.01% 7484
2014
Q2 		$5K Buy
780
+641
+461% +$4.08K ﹤0.01% 7164
2014
Q1 		$1K Buy
+139
New +$824 ﹤0.01% 7541
2013
Q4 		– Sell
-2,200
Closed -$7K – 8008
2013
Q3 		$7K Buy
+2,200
New +$7.66K ﹤0.01% 6918

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's NWBO Position: Q3 2016 in Review

Barclays sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2016, closing a stake of 5,467 shares — an estimated $3K sold.

Barclays first reported a position in NWBO in Q3 2013 and held it in 9 quarters. The position peaked at $11K in Q4 2014. 54 funds tracked by Wall St. Rank hold NWBO as of Q3 2016.

  • Barclays reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2016 after selling out during the quarter.
  • Barclays sold 5,467 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2016, an estimated $3K.
  • Barclays first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2013 and held it in 9 quarters.
  • Barclays's Northwest Biotherapeutics, Inc. Common stock position peaked at $11K in Q4 2014.
  • 54 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2016.

Based on Barclays's 13F filing for Q3 2016, filed 14 Nov 2016.